HNGE’s digital back-pain play: fast growth, real profits

The thesis

Hinge Health (HNGE) is turning app-based physical therapy for back and joint pain into a real business with strong growth and actual cash profits. In Q1 2026, revenue jumped 47% year over year to about $182 million, with very high 85% gross margins and free cash flow of $41.6 million.[1] Management raised full‑year 2026 revenue guidance to roughly $798–804 million and expects operating income (after day‑to‑day costs) of $205–215 million, a 26% margin.[1] The near-term spark is the August 4, 2026 Q2 earnings call, where they’ve already guided to 40%+ revenue growth and stronger operating profit.[1][4] If they also announce new employer wins or insurer deals, the story shifts from “promising” to “proven platform.”

Everyone wishes they'd bought Nvidia early. Here's how to spot the next one.

The biggest winners of the last decade had one thing in common. Our data follows those exact moves — and turns them into 10 names to watch right now.

The big names in the AI, Space, Nuclear and Robotics race. The window to get in early is closing fast. Don't wait.

See the top 10 stocks now — free ›

💡 Why this matters

Most adults either have back pain now or will someday, and employers spend a fortune on it. Hinge Health offers virtual physical therapy and care teams through your phone instead of sending people straight to surgery or expensive imaging. That fits two big trends: healthcare moving online, and companies trying to cut medical costs without cutting benefits.[1] On top of that, Hinge leans on software and automation to guide exercises and track progress, which lines up with the wider move toward AI and smart workflows in real-world services, not just chatbots.[1] If they keep proving they can save money and avoid surgeries, more employers and insurers are likely to sign on.

▲ Catalysts

+ Q2 2026 earnings release and call on August 4, 2026, with guided revenue of about $194–196 million and 25% operating margin.[1][4]
+ Full-year 2026 guidance of roughly $798–804 million revenue and $205–215 million operating income, which could be raised again if momentum continues.[1]
+ Potential new deals with large employers or health plans adopting Hinge’s digital musculoskeletal program to cut surgery and imaging costs.[1]
+ Growing investor attention if HNGE delivers another earnings beat after Q1 2026 EPS of $0.45 crushed expectations.[2]

▼ Risks

! If growth slows below the current 40%+ pace, the stock could rerate quickly as expectations reset.[1][2]
! Large insurers or hospital systems could launch competing digital therapy programs and pressure Hinge’s pricing and margins.
! Employers might cut back on wellness benefits in a tougher economy, delaying or cancelling Hinge rollouts.
! Any stumble in app quality, results data, or regulatory scrutiny around digital care could hurt trust with customers.

🎯 One thing to take away

HNGE is a fast-growing digital health company focused on back and joint pain, selling virtual physical therapy and care teams to employers and health plans. It’s not just a story stock: revenue grew 47% in Q1 2026, margins are high, and the business is already throwing off cash.[1] Management just raised full‑year guidance and is calling for strong growth and solid profit again in Q2, with results coming August 4.[1][4] The upside case is that Hinge becomes a go‑to benefit for big employers trying to avoid pricey surgeries. The flip side is that expectations are now high, and any slowdown, competition, or benefit cutbacks could sting. It’s a name worth watching if you’re interested in digital healthcare tied to real cost savings, not just hype.

Data sources & methodology

All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →

TZ Researched & published by TradesZ Research

Want our premium picks too?

Pro subscribers get our strongest pre-pop ideas + real-time buy-zone alerts.

Thinking about HNGE?

Our data likes 10 other stocks even more right now — under-the-radar names we believe have monster upside potential. Get the free list before the crowd catches on.

Show me the 10 stocks — free →

Free · no credit card · unsubscribe in one click

Not investment advice. We share research and analyses for educational purposes. Investing in stocks involves risk, including possible loss of capital. Always do your own research.